Welcome to our EJNMMI Journal Family page, which highlights some of our featured content and the latest developments from the EJNMMI group of journals.
Stay up to date with article collections, editor’s highlights, upcoming events, and read our latest research!
Our EJNMMI Journal Family Editors-in-Chief 2020
(from left to right): Francesco Giammarile, Stefaan Vandenberghe, Philip Elsinga, Angelika Bischof Delaloye, Arturo Chiti
Highly ranked among journals in its field, the European Journal of Nuclear Medicine and Molecular Imaging provides a forum for the exchange of clinical and scientific information for the nuclear medicine community and allied professions involved in the functional, metabolic and molecular investigation of disease. Find out more about the journal or read our latest content.
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease. Learn more.
EJNMMI Physics is an international platform for scientists, users and adopters of nuclear medicine with a particular interest in physics matters. As a companion journal to the European Journal of Nuclear Medicine and Molecular Imaging, this journal has a multi-disciplinary approach with a focus on applied physics and mathematics as well as imaging systems engineering and prototyping in nuclear medicine. Learn more.
EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The open access journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. Learn more.
The European Journal of Hybrid Imaging publishes new basic and clinical research in the field of imaging, conducted with hybrid or multimodality techniques. The unique characteristic of this journal is the focus on hybrid and multimodality imaging technology in different clinical and research fields: oncology, neurology, cardiology, orthopedics, infection imaging. Learn more.
Topical Collections about latest and interesting topics in nuclear medicine and molecular imaging are available at: https://link.springer.com/journal/259/collections
Future Congress
37th Annual Congress of the European Association of Nuclear Medicine
October 19 – 23, 2024
Hamburg, Germany
CCH – Congress Center Hamburg
Congressplatz 1
20355 Hamburg, Germany
URL: https://www.cch.de/en/
EJNMMI is part of the EJNMMI Journal Family. Highlights of our featured content and the latest developments from the EJNMMI group of journals can be found on the EJNMMI Journal Family webpage. There details about the annual EANM Springer Award are available as well.
The EANM Springer Prize is awarded virtually and annually on the occasion of the EANM congress. With these awards for all journals within the EJNMMI Journal Family the Editors-in-Chief want to appreciate the outstanding work of researchers in the field of nuclear medicine and molecular medicine.
Congratulations to all winners by now!
Please consult https://www.eanm.org/congresses-events/awards-grants/winners./ for an overview of the award winners and the best papers.
Details of the OpenChoice option in EJNMMI are available in the submission guidelines.
If your institution has a Read and Publish (Springer Compact) agreement, you may publish your article open access at no cost to you. In addition, you can enjoy full access to all Springer subscription journal content.
Please check the agreement details by participating country here.
As of April 1st, 2021 EJNMMI Research has a new Editor-in-Chief. Please welcome Wim J. G. Oyen.
Thank you very much to Angelika Bischof Delaloye for establishing EJNMMI Research as Editor-in-Chief since the launch of the journal in 2011.
Nuclear medicine is a vibrant and rapidly developing field in biomedical research. Within the family of EJNMMI journals, EJNMMIresearch focuses on translational research, aiming to be the bridge between basic and and clinical research in nuclear medicine, molecular imaging as well radioligand-based therapy and related concepts of targeted therapies. EJNMMIresearch positions itself at the cross-roads of innovative research in biology, genetics, immunology, medicine, radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation.
EJNMMIresearch encourages submission of original, cutting-edge basic, translational and early clinical research. This includes rapid communication of proof-of-concept or even preliminary findings. EJNMMIresearch also welcomes submission of state-of-the-art educational papers, reviews and short communications. Editorials and Letters-to-the-Editor are an integral and indispensable part of lively interaction within the scientific community to exchange thoughts and opinions. Occasionally, case reports will also be considered. EJNMMIresearch’s fully Open Access model of publication facilitates rapid processing after rigorous peer review of the submitted manuscripts.
As an established member of the five Journals in the EJNMMI family of Journals (www.springeropen.com/p/nuclear-medicine), EJNMMIresearch also encourages high-quality submissions, which are within the scope of EJNMMIresearch, but cannot be acccomodated by the other Journals in the family. Conversely, original manuscripts not accepted by EJNMMIresearch may prove to be a better fit with other Journals in the family.
On behalf of the entire EJNMMIresearch team, thank you for considering EJNMMIresearch as the journal to publish your research.
Wim J.G. Oyen, Editor-in-Chief
Humanitas University Milan, Italy and Rijnstate Arnhem, The Netherlands